(Q44489047)

3 December 2017

title

Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (Rituximab). (English)

1 reference

3 December 2017

1 reference

1 reference

pemphigus vulgaris

1 reference

1 reference

2

1 reference

3 December 2017

Cooper HL

1

1 reference

3 December 2017

Theaker JM

series ordinal

3

1 reference

3 December 2017

Friedmann PS

series ordinal

4

1 reference

3 December 2017

publication date

1 July 2003

1 reference

Clinical and Experimental Dermatology

3 December 2017

published in

1 reference

3 December 2017

volume

28

1 reference

3 December 2017

issue

4

1 reference

3 December 2017

page(s)

366-368

1 reference

Detection of antigen-specific B cells in patients with pemphigus vulgaris by enzyme-linked immunospot assay: requirement of T cell collaboration for autoantibody production.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2003.01283.X

Epitope spreading: lessons from autoimmune skin diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2003.01283.X

Treatment of refractory antibody mediated autoimmune disorders with an anti-CD20 monoclonal antibody (rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2003.01283.X

Humoral immunity due to long-lived plasma cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2003.01283.X

Hapten-induced primary and memory humoral responses are inhibited by the infusion of anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab).

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2003.01283.X

Treatment of pemphigus with intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2230.2003.01283.X

10.1046/J.1365-2230.2003.01283.X

21 January 2018

Identifiers

DOI

1 reference

3 December 2017

1 reference